Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary therapies to enhance the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It develops COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages in Phase 2 trial for use in the treatment of amyotrophic lateral sclerosis, as well as frontotemporal dementia, Alzheimer's disease (AD), and Parkinson's disease. In addition, the company's pre-clinical product candidates include COYA 301, a low-dose interleukin 2 product candidate to treat AD; COYA 303, an investigational biologic combination of COYA 301 and a glucagon-like-peptide-1 receptor agonist for the treatment of inflammatory diseases; COYA 201, an antigen directed Treg-derived exosome product candidate to treat neurodegenerative, autoimmune, and metabolic diseases; COYA 206, an antigen directed Treg-derived exosome product candidate; and COYA 101. It has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. Coya Therapeutics, Inc. was founded in 2020 and is headquartered in Houston, Texas. Show more
Location: 5850 San Felipe St., Houston, TX, 77057, United States | Website: https://coyatherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
111.9M
52 Wk Range
$4.65 - $10.24
Previous Close
$6.69
Open
$6.67
Volume
73,548
Day Range
$6.00 - $6.80
Enterprise Value
81.3M
Cash
29.76M
Avg Qtr Burn
-4.118M
Insider Ownership
7.12%
Institutional Own.
27.03%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
COYA 301 (Low Dose IL-2) Details Alzheimer's disease, Neurodegenerative disease | Phase 2 Data readout | |
COYA 302 Details Amyotrophic lateral sclerosis | Phase 2 Initiation | |
COYA 302 (Low Dose IL-2 + CTLA4-Ig) Details Frontotemporal dementia | Phase 1 Data readout |